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Multidrug-resistant tuberculosis (MDRTB) is a serious world health problem that limits pub-
lic  actions to control tuberculosis, because the most used anti-tuberculosis ﬁrst-line drugs
fail  to stop mycobacterium spread. Consequently, a quick detection through molecular diag-
nosis  is essential to reduce morbidity and medical costs. Despite the availability of several
molecular-based commercial-kits to diagnose multidrug-resistant tuberculosis, their diag-
nostic value might diverge worldwide since Mycobacterium tuberculosis genetic variability
differs according to geographic location.
Here, we studied the predictive value of four common mycobacterial mutations in strains
isolated from endemic areas of Brazil. Mutations were found at the frequency of 41.9% for
katG,  25.6% for inhA, and 69.8% for rpoB genes in multidrug-resistant strains. Multimarker
analysis revealed that combination of only two mutations (“katG/S315T + rpoB/S531L”) was a
better surrogate of multidrug-resistant tuberculosis than single-marker analysis (86% sensi-
tivity vs. 62.8%). Prediction of multidrug-resistant tuberculosis was not improved by adding
a  third or fourth mutation in the model. Therefore, rather than using diagnostic kits detec-
ting several mutations, we propose a simple dual-marker panel to detect multidrug-resistant
tuberculosis, with 86% sensitivity and 100% speciﬁcity. In conclusion, this approach (previ-ous  genetic study + analy
processing costs while ret
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ntroduction
uberculosis (TB) remains an important public health concern
s about one third of the world population is asymptomati-
ally infected with latent Mycobacterium tuberculosis.1 Multiple
ealth campaigns are being addressed to diminish the inci-
ence of the disease, but TB elimination remains a challenge,
ue to the emergence of clinical forms of multidrug-resistant
trains of M. tuberculosis,1 that are resistant to at least isoniazid
INH) and rifampicin (RIF), the ﬁrst-line antitubercular (anti-
B) drugs. Beyond increasing TB incidence, mortality, and the
ate of initial treatment failure, multidrug-resistant tubercu-
osis (MDRTB) also increase the cost of TB treatment.1 For
xample, while a 6-month regimen of INH + RIF (plus pyraz-
namide and streptomycin or ethambutol in the ﬁrst two
onths) will cure most cases of non-resistant TB, MDRTB-
atients will need at least 12–24 months of therapy with more
oxic second-line drugs.1,2 In addition, MDRTB accounts for up
o 84% of the “retreatment” cases of TB.1 With this perspec-
ive, early diagnosis appears to be the best strategy to control
DRTB.1
Conventional culture-based drug-susceptibility testing
DST) for TB can take as much as 90 days to complete, due
o the slow growth of M. tuberculosis.3 Since diagnostic delay
s an arduous obstacle to effective MDRTB care, development
nd implementation of molecular approaches for rapid detec-
ion of MDRTB  are needed for attenuating the MDRTB  burden.
owards that end, many  studies have investigated gene muta-
ions that confer drug resistance in M. tuberculosis.4–6 As a
esult, many  commercial tests have been developed to detect
DRTB and, consequently, the WHO  recommends to all gov-
rnments the gradual implementation of evidence based
ommercial tests using molecular techniques for diagnosis
nd control of MDRTB.1
Overall, these tests aim to detect mutations in the
ycobacterial genes involved in drug metabolism, which may
onfer phenotypic changes associated with antibiotic resis-
ance. In this way, INH resistance is frequently associated
ith mutations in the catalase-peroxidase enzyme (encoded
y the katG gene and involved in metabolic activation of
he drug),5 and/or in the enoyl-ACP reductase gene promoter
inhA), required for mycobacterial cell wall biosynthesis.7 Like-
ise, resistance to RIF is strongly related to mutations in a
egion of 81 bp in the rpoB gene (encoding the beta subunit of
he RNA polymerase, the drug target),3,8 resulting in decreased
fﬁnity of RIF for the active centre of the enzyme.9 Mutations
n several other genes may also lead to INH or RIF resistance
ut are less frequent.10–12 Thus, common gene markers for
DRTB are S315T in katG, −15C/T (CGT-CAT) in the operator
egion of inhA, and H526D and S531L in rpoB.4,5
Diagnostic parameters, such as sensitivity and speciﬁcity,
f commercially available diagnostic tests are poorly under-
tood in a worldwide context.1 This is of interest since
here is evidence that geographic location inﬂuences on the
train-to-strain M.  tuberculosis genetic variability.13–15 In this
ontext, current gold-standard molecular biomarkers to diag-
ose MDRTB  might not be found at reasonable frequencies
o guide anti-TB drug choice in neglected regions such as
razil. Moreover, it is even possible that non-trivial mutations6;2 0(2):166–172 167
could turn out to be novel biomarkers for MDRTB diagnosis
in such regions. In this regard, we genotyped four mycobacte-
rial SNPs (single nucleotide polymorphisms) in isolates from
TB patients of an endemic region of Brazil to investigate their
predictive value to diagnose MDRTB, and using these new ref-
erence standards as gold-standard. Our aim was to test and
validate a rapid and cost-effective real-time PCR assay for
detecting RIF and INH resistance.
Methods
Isolation,  identiﬁcation  and  drug  sensitivity  tests  of  M.
tuberculosis
M.  tuberculosis isolates were considered as MDRTB when resis-
tant to at least INH and RIF (worldwide used as ﬁrst-line
antitubercular drugs), and as sensitive when susceptible to all
anti-tubercular drugs. Therefore, mono-resistant strains for
INH or RIF, as well as other poly-drug-resistance not including
both INH and RIF were not considered for further experiments
in our study. These isolates were randomly selected and col-
lected from a repository located at the Central Public Health
Laboratory “Prof. Gonc¸alo Muniz” (LACEN-BA), state of Bahia,
Brazil. All isolates from the collection come from sputum of
local patients which completed a demographic and clinical
questionnaire after signing an informed consent form. All pro-
cedures were approved by the Human Ethical Committee of
the Universidade Estadual de Santa Cruz (UESC; Ilhéus, Brazil),
under protocol number 098/07.
The selected samples were cultivated on Löwenstein-
Jensen agar (LJ). Biochemical tests, including nitrate reduction,
niacin test and 68 ◦C catalase inhibition were conducted
in order to classify these strains according to the Man-
ual of Tuberculosis Bacteriology.16 Drug sensitivity tests to
INH, RIF, ethambutol (EMB), pyrazinamide (PZA), and strepto-
mycin (SM) were performed using the Canetti (1969) multiple
proportional dilution method.17 The standard strains M. tuber-
culosis H37Rv and 636 were used as sensitive and MDRTB
controls, respectively, as recommended by the Brazilian Min-
istry of Health.16 The minimum inhibitory concentrations
(MIC), deﬁned as the lowest drug concentration showing
complete inhibition of bacterial growth, were as follow:
INH ≤ 0.2 g/mL, RIF ≤ 1 g/mL, EMB ≤ 5 g/mL, SM ≤ 2 g/mL,
and PZA ≤ 25 g/mL. The criterion for drug resistance was
growth of ≥1% of the bacterial population on media containing
the critical concentration of each drug.
Genotyping  assay  and  ampliﬁcation
Mycobacterial genomic DNA was extracted from the cultured
strains according to Van Soolingen et al.18 The quantity and
purity was determined measuring spectrophotometric signals
at 260 nm and 280 nm.
Assays were performed, in accordance to Espasa et al.,19
in a spectroﬂuorometric thermal cycler (ABI Prism 7500,
Applied Biosystems®, Carlsbad, CA, USA), using the primers
and probes summarized in Table 1. The Mycobacterium tuber-
culosis Complex-Speciﬁc Insertion Sequence IS6110 was also
ampliﬁed as internal control. Five ampliﬁcation reactions were
168  b r a z j i n f e c t d i s . 2 0 1 6;2  0(2):166–172
Table 1 – Primers and probes designed to detect mutations included in the study.
Gene
(codon)
Primers  Probes
IS6110a 5′-GGATAACGTCTTTCAGGTCGAGTAC-3′
5′-TCGCCTACGTGGCCTTTG-3′
5′-GGATAACGTCTTTCAGGTCGAGTAC-3′
katG (315) 5′-GGGCTGGAAGAGCTCGTATG-3′
5′-GGAAACTGTTGTCCCATTTCG-3′
5′-CGACCTCGATGCCGCTGGTGAT-3′
5′-CGACCTCGATGCCGGTGGTGAT-3′
inhA (−15) 5′-CACGTTACGCTCGTGGACAT-3′
5′-CAGGACTGAACGGGATACGAA-3′
5′-AACCTATCGTCTCGCCGCGGC-3′
5′-AACCTATCATCTCGCCGCGGC-3′
rpoB (526) 5′-ACCGCAGACGTTGATCAACAT-3′
5′-GGCACGCTCACGTGACAG-3′
5′-CGCTTGTGGGTCAACCCCGA-3′
5′-CGGCGCTTGTAGGTCAACCCC-3′
rpoB (531) 5′-ACCGCAGACGTTGATCAACAT-3′
5′-GGCACGCTCACGTGACAG-3′
5′-AGCGCCGACAGTCGGCG-3′
5′-CAGCGCCAACAGTCGGCG-3′
rized in Table 4 (note that combinations with H526 from rpoB
were excluded due to the lack of statistical signiﬁcance to
detect drug resistance). Among them, only model 1 (S315T
Table 2 – Drug resistance proﬁle in samples randomly
obtained from biobank.
Resistance to each
drug
wt strains
(n = 50)a
Resistant strains
(n = 51)a
INHb 0 (0) 100.0% (51)
RIFb 0 (0) 84.3% (43)
EMB 0 (0) 5.9% (3)
SM 0 (0) 54.9% (28)
PZA 0 (0) 47.1% (24)
Basal medium w/o
antibiotics
100% (50) 100% (51)
aa Mycobacterium tuberculosis Complex-Speciﬁc Insertion Sequence.
performed for each studied sample. Brieﬂy, the reaction con-
tained: 1X Master Mix  solution, 500 nM of each primer, 200 nM
of ﬂuorogenic 5′ exonuclease probes (Taqman®, Applied
Biosystems®, Foster City, CA, USA), and 4 L (20 ng/L) of sam-
ple in 25 L of reaction volume. The ampliﬁcation settings
were carried out according to the manufacturer’s instructions.
Analysis of the results was performed using the Sequence
Detection System software (Applied Biosystems®) and was
based on two parameters: the cycle threshold (CT), for which
the detection of ﬂuorescence reaches the threshold, and the
cumulative ﬂuorescence signal (CFS) of each probe at the end
of 40 ampliﬁcation cycles.
Statistical  analysis
Pearson chi-square test was applied to evaluate differences
in genotypic frequencies between sensitive and resistant
isolates. Discriminant analyses were performed to build pre-
dictive models of INH and RIF resistance based on genotyping
data of the four genetic markers used, alone or in combi-
nation. Comparison of the observed genetic frequencies was
performed using UNPHASED software (v.3.1.7).20 Statistical
measures of sensitivity and speciﬁcity were performed using
IBM SPSS Statistics version 20 (SPSS Inc., Armonk, NY, USA)
with a 95% conﬁdence interval. The p-value signiﬁcance was
always set at 5% (p < 0.05).
Results
First, a conﬁrmatory sensitivity test was performed on a total
of 51 resistant and 50 sensitive catalogued strains (Table 2).
From those, 43 (84.3% of resistant-strains) were considered
as MDRTB  strains exhibiting resistance to both INH and RIF,
and were selected for further experiments. Six of the strains
showed drug-resistance to only one antibiotic (INH), and
only two exhibited multi-resistance other than INH and RIF
together. The other 50 strains, catalogued as sensitive, were
in deed conﬁrmed to be sensitive to all ﬁve antibiotics tested,
and were used as negative controls.
Frequency  of  polymorphisms  in  katG,  inhA  and  rpoB
genes  and  their  association  with  drug  resistance
As expected,4,5 none of the studied mutations was found
in drug-susceptible strains (Table 3). Although this ﬁndingsuggests that absence of the analyzed katG, inhA, and rpoB
mutations is indicative of non-MDRTB strains with 100% speci-
ﬁcity, it is noteworthy that a small number of MDRTB samples
(14%, n = 6) also lacked these mutations (Table 3). Thus, our
data reveal that the absence of these common katG, inhA, and
rpoB mutations does not necessarily assure non-MDRTB.
Conversely, we found that the occurrence of any of the
mutations translates identiﬁcation of MDRTB. Among the 43
strains studied for MDRTB, 18 displayed the S315T (katG) muta-
tion, 11 had the −15C/T (inhA) whereas, 3 and 27 strains
showed H526D and S531L polymorphisms, respectively, in rpoB
(Table 3). Although displaying 100% speciﬁcity, sensitivity to
detect MDRTB varies according to the identiﬁed mutation.
Mutations with greater sensitivity (62.8%) were S531L (rpoB),
followed by S315T (katG) and −15C/T (inhA), with 41.9% and
21.6%, respectively (Table 3). The H526 mutation (rpoB) showed
only 7% sensitivity without statistically signiﬁcance to detect
drug resistance.
Given that bacteria may reduce effectiveness of a drug
through various biological mechanisms at the same time, we
addressed whether diagnosis sensitivity could be greater than
62.8% (displayed by the single marker S315T katG) in pre-
diction models including multiple mutations. In this regard,
we structured four models of two or three SNPs, as summa-Previously catalogued as wt or resistant-strains by biochemical
tests. Values are % of n (absolute values).
b Resistance to both INH and RIF was deﬁned as Multi Drug Resis-
tance (MDRTB).
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Table 3 – Frequency of mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis strains.
Mutation
(gene)
Frequency in
susceptible strains
(n = 50)a
Frequency in MDRTB
strains (n = 43)a
X2  b p-Valuec
S315T
(katG)
0  (0) 41.9% (18) 25.953 <0.001
−15C/T
(inhA)
0 (0) 25.6% (11) 14.507 <0.001
H526D
(rpoB)
0 (0) 7.0% (3) 3.605 0.095
S531L
(rpoB)
0 (0) 62.8% (27) 44.239 <0.001
None of
above
100% (50) 14.0% (6) – –
a Previously characterized by biochemical tests. See Table 1. Values are % of n (absolute values).
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c p-Values from comparison between susceptible and resistant strain
atG + −15C/T inhA) model did not reach the “basal” sensi-
ivity of 62.8%. The gain in sensitivity of model 2 (S531L
poB + −15C/T inhA) was only about 2.3%, when compared
o the best single marker. In contrast, models 3 (S315T
atG + S531L rpoB) and 4 (S315T katG + S531L rpoB + −15C/T
nhA) showed a considerable gain in diagnosis sensitivity, by
ncreasing this parameter by 23.2%. Using the last two models,
e identiﬁed 37 out 43 MDRTB  strains carrying at least one of
he analyzed markers. Thus, taken in consideration that both
odels have identical diagnostic predictive values, this sug-
ests that it is unnecessary to genotype three of the studied
olymorphisms to achieve greater sensitivity.
iscussion
t is evident that strains, as well as type of mutations and
requency of them in mycobacterial genome, vary accord-
ng to the geographical region.21,22 Consequently, since the
ccuracy of current molecular diagnostic tests to identify
DRTB are based on worldwide polymorphisms frequencies,
erformance indicators for these diagnostic approaches in a
ountry-by-country basis may be controversial. For example,
he S315T (katG) polymorphism shows a wide variation in their
ncidence: although it was detected in a 100% of resistant
23–25trains in countries such as Turkey, Canada, and France,
n our study we  found a lower frequency of 41.9%, more  sim-
lar to those obtained in another study in Brazil (60%) and in
laces such as Russia (77%), Syria (40%) or Taiwan (51%).13,26–28
Table 4 – Predictive proﬁle of polymorphisms in katG, inhA and 
Mycobacterium tuberculosis strains.
Genes Polymorphisms 
katG or inhA S315T & −15C/T 
inhA or rpoB −15C/T & S531L 
katG or rpoB S315T & S531L 
katG or inhA or rpoB S315T & −15C/T & S531L 
a Previously characterized by biochemical tests. Values are % of n (absolutld values were considered statistically signiﬁcant.
Likewise, the −15C/T (inhA) polymorphism, described as the
one most frequent globally for the inhA gene promoter,5,29 has
an observed frequency varying between 15% in China30 to 32%
in Syria,13 and 25.6% in this study. Also, the frequency of 62.8%
for S531L (rpoB) found in this work was consistent with other
studies, considering that published rates range between 40.1%
and 82.4%.31–34 In the same way, H526D (rpoB) polymorphism,
with a found frequency of 7% in this work amply oscillates
worldwide, with values ranging from 5.9% to 40%.31,34 There-
fore, great frequency variations are evident between countries,
making it necessary to study locally the prevalence of the
canonical mutations for each geographical region in order
to ﬁgure out which polymorphisms have the best predictive
accuracy.
As early diagnosis is the best strategy to control MDRTB,
several molecular methods to detect drug resistance in M.
tuberculosis are currently widely employed.35 For that, a num-
ber of commercial kits to identify MDRTB are available,
such as Xpert MTB/RIF® (Cepheid, Sunnyvale, CA, USA) and
INNO-LiPA Rif.TB (Innogenetics N.V., Gent, Belgium), among
others, which detect resistance to only rifampicin not to
isoniazid.36,37 The rational for assessing only mutations asso-
ciated RIF-resistance is that some reports have suggested
that RIF-resistance seems to serve as a surrogate marker for
MDRTB detection,38,39 as almost all RIF-resistant strains were
also INH-resistant. In our study, we found also that 100% of
RIF-resistant strains were also INH-resistant (Table 2). Nev-
ertheless, this ﬁnding depends of the endemic strains of
M.  tuberculosis in each geographical region,21,22 as discussed
rpoB genes related to multidrug resistance in
Statistical models Frequency in resistant
strainsa (n = 43)
Model 1 60.5% (26)
Model 2 65.1% (28)
Model 3 86.0% (37)
Model 4 86.0% (37)
e values).
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Table 5 – Comparative parameters of molecular
diagnosis of Multidrug Resistant Tuberculosis between
this study and published data for Xpert MTB/RIF.
Analytical variables This work Xpert MTB/RIFa
Sensitivity 86.0% 89.2–91.4%
Speciﬁcity 100.0% 98.0–98.7%
No. of polymorphisms
studied
2  5
Chemotherapy resistance
studiedb
INH, RIF RIF
Time (DNA extraction + PCR
reaction)
3 h 2  h
Test/day (considering a
work day of 8 h)
20–30 8–16c
Price of 1 test US$ 8.53 US$ 9.98–16.86d
a Source: Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis
of tuberculosis and rifampicin resistance with Xpert mtb/rif
assay: A meta-analysis. J Infect 2012; 64(6): 580–588.45
http://www.ﬁnddiagnostics.org/about/what we do/successes/ﬁnd-
negotiated-prices/xpert mtb rif.html.43
b INH: isoniazid; RIF: Rifampicin.
c Xpert machine with two or four cartridges, respectively.170  b r a z j i n f e c t d 
above. In this way, some reports from the Punjab region of
India40,41 have shown a high incidence of RIF-monoresistant
strains (22%) that would be falsely diagnosed as MDRTB using
these type of test. The Xpert® MTB/RIF assay, much cheaper
than INNO-LiPA Rif.TB (approximately US$17 and US$45 per
test, respectively),42,43 has been recommended by the World
Health Organization for the detection of MDRTB from 2010,
and is exhaustively implemented worldwide.1,44 However,
only a limited number of tests can be performed per day, mak-
ing it necessary to acquire several machines per laboratory.
Furthermore, the cost per test,45 even if negotiated for public
institutions by the FIND organization43 (Foundation for Inno-
vative New Diagnostics, Geneva, Switzerland) (Table 5), makes
our system an interesting cost/beneﬁt diagnostic tool for our
local area. In addition, these kits have sensitivity and speci-
ﬁcity to detect drug resistance similar to those shown in this
study36,37,45 (Table 5).
Recently, there has been reported a more  accurate commer-
cial kit, the GenoType MTBDRplus (Hain Lifescience, Nehren,
Germany) which has higher sensitivity than competitors (up
to 94.4%) and could detect even resistance to both INH and
RIF.46 Nevertheless, it requires the analysis of up to 10 markers
to diagnose MDRTB, whereas Xpert® MTB/RIF and INNO-LiPA
Rif.TB use 5 and 4, respectively,42,43 increasing even more  the
processing costs (between D 42 and D 86 per test).47 In our
study, the proposed analysis of polymorphisms to diagnose
MDRTB in the Bahia state of Brasil, has a high sensitivity (86%)
even if only two genetic markers are analyzed.
In our case (Bahia state of Brazil), after identiﬁcation of the
prevalent polymorphisms, the protocol for MDRTB analysis,
(Fig. 1) would consist in extracting the DNA from M. tuberculo-
sis directly from sputum samples. Then the samples would be
subjected to genotyping for the detection of polymorphisms at
S531L rpoB and S315T katG genes. Presence of S531L (62.8% of
incidence in endemic mycobacteria) or S315T (41.9%) muta-
tions in the samples would be diagnosed as MDRTB (86% of
Suspected  Multidrug-Resista 
Genotyping S315T mutat
S531L mutation i
Detection of polymorphism
in S315T katG gene?
N
YES Classical Bio
Sensiti vit y
MDRTB
(41.9%) MDRTB
(14.0%)
Combined ap
MDRTB (8
YES 
Fig. 1 – Algorithm for the diagnosis of Multidrug Resistance Tube
isoniazid and rifampicin resistance.d Negotiated price for the public sector in eligible countries and real
price, respectively.
cases, carrying anyone of the two mutations). The speciﬁcity
of 100% coupled with high accuracy, easy operation, and low
cost (due to the smaller number of markers used), makes it a
great method to be used in routine diagnosis of MDRTB. Our
work shows that combining a few markers, without the need
of an extensive panel of analysis, is sufﬁcient to improve the
accuracy for the detection of both RIF- and INH-resistance in
our region.Our results came as no surprise, considering that most
RIF-resistance mutations occur close to the S531 residue,48
and almost all RIF-resistant strains are also INH-resistant.38,39
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oreover, the S315T mutation is the most frequently found
n INH-resistant strains that are also MDRTB, occurring in
pproximately 40% of all cases.49
For the small percentage of false-negative samples (14%),
onventional culture and drug sensitivity techniques can be
erformed as conﬁrmatory tests, as 86% of the multidrug-
esistant population will be previously diagnosed in both
ffective and early-time manners. In this context, even if fur-
her studies should be conducted to establish other markers
o increase even more  the sensitivity of the proposed algo-
ithm (Fig. 1), taken together our results have shown that in
rder to provide a fast, sensitive and low-cost diagnosis, the
roposed PCR-based protocol would be sufﬁciently appropri-
te for our geographical region. As demonstrated previously
y Madania et al.,13 in Syria, a small set of probes detecting
revalent mutations can be used in real time PCR in order to
etect most strains carrying RIF- and INH-resistance. In the
ame way, we  propose that our algorithm can be revised and
mplemented in other countries besides Brazil, by conduct-
ng a simple genetic background evaluation of their endemic
opulations of M.  tuberculosis.
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